Anzeige
Mehr »
Freitag, 21.08.2026 - Börsentäglich über 12.000 News
Washington beschleunigt New Amalga: Die US-Regierung verändert die Grande-Portage-Story
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCUH | ISIN: SE0014855029 | Ticker-Symbol: 8IM1
Tradegate
20.08.26 | 20:35
4,835 Euro
-1,02 % -0,050
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMPLANTICA AG SDR Chart 1 Jahr
5-Tage-Chart
IMPLANTICA AG SDR 5-Tage-Chart
RealtimeGeldBriefZeit
4,8054,95520.08.
4,8354,93020.08.

Aktuelle News zur IMPLANTICA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06:10Implantica erhält FDA-Zulassung für Reflux-Implantat RefluxStop1
05:54Implantica receives FDA approval for GERD implant RefluxStop2
05:42Implantica receives FDA approval for RefluxStop - Opening the U.S. market209VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S....
► Artikel lesen
14.08.Implantica presents the second quarter (Q2 2026) on August 21 at 15:00 CEST4
10.06.Implantica AG: Bulletin from the Annual General Meeting of Implantica AG191Today, June 10, 2026, the annual general meeting (the "AGM") of Implantica AG (publ) was held in Ruggell, Liechtenstein. The general meeting resolved to adopt all of the board of directors' resolution...
► Artikel lesen
IMPLANTICA Aktie jetzt für 0€ handeln
09.06.Implantica announces launch of 20th RefluxStop Center of Excellence in Spain, part of a world-renowned US hospital group388VADUZ, Liechtenstein, June 9, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop...
► Artikel lesen
22.05.Implantica publishes Interim Report January - March 2026 (Q1)555VADUZ, Liechtenstein, May 22, 2026 /PRNewswire/ -- Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStopSignificant events in the first quarter of 2026Secured over...
► Artikel lesen
21.05.Notice of Annual General Meeting of Implantica AG402VADUZ, Liechtenstein, May 21, 2026 /PRNewswire/ -- The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to...
► Artikel lesen
21.05.Implantica announces publication of a new health economics study showing RefluxStop's superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System8
20.05.Implantica submits final response to FDA in the PMA application for RefluxStop for U.S. market approval1.151VADUZ, Liechtenstein, May 20, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including...
► Artikel lesen
19.05.Implantica announces new breakthrough long-term RefluxStop data on severe sufferers presented at DDW 2026912VADUZ, Liechtenstein, May 19, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop...
► Artikel lesen
19.05.IMPLANTICA: RefluxStop gains momentum at DDW 20262
18.05.Implantica presents the first quarter (Q1 2026) on May 22 at 15:00 CET312VADUZ, Liechtenstein, May 18, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the first quarter 2026 at 15:00 CET on May 22. The interim report for the first...
► Artikel lesen
06.05.Implantica publishes Annual Report 2025397VADUZ, Liechtenstein, May 6, 2026 /PRNewswire/ -- Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report...
► Artikel lesen
21.04.Implantica announces landmark RefluxStop study of 602 patients across 22 European centers, with up to 6.75-year follow-up, published in Nature's Scientific Reports528VADUZ, Liechtenstein, April 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop...
► Artikel lesen
26.03.Implantica publishes Year-end Report, January - December 2025 (Q4)485VADUZ, Liechtenstein, March 26, 2026 /PRNewswire/ -- RefluxStop US Launch Coming Closer, pending FDA approvalSignificant events in the fourth quarter FDA completed six pre-approval...
► Artikel lesen
25.02.Implantica AG: Implantica publishes Year-end Report, January - December 2025 (Q4)931RefluxStop® US Launch Coming Closer, pending FDA approval Significant events in the fourth quarter FDA completed six pre-approval inspections during the quarter - including manufacturing sites,...
► Artikel lesen
18.02.Implantica presents the Year-end Report (Q4 2025) on February 25 at 15:00 CET614VADUZ, Liechtenstein, Feb. 18, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q5 2025) at 15:00 CET on February 25. The Year-end Report...
► Artikel lesen
27.01.Implantica announces major public tender wins in Italy securing over EUR 1.2 million funding for RefluxStop1.160VADUZ, Liechtenstein, Jan. 27, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
10.12.25Implantica strengthens market expansion as Italy's leading Careggi University Hospital in Florence introduces RefluxStop739VADUZ, Liechtenstein, Dec. 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1